Pataigin

Executive Summary

Pataigin is a private biotechnology company based in Cambridge, Massachusetts, developing a novel rapid diagnostic platform that leverages MALDI mass spectrometry to identify bacterial and fungal pathogens directly from clinical specimens and determine antimicrobial resistance in as little as one hour. Its lead product, BACLIB, aims to replace traditional multi-day culture methods, potentially transforming the management of serious infections by enabling same-day, targeted antibiotic therapy. This could significantly improve patient outcomes, reduce hospital stays, and combat antimicrobial resistance. Founded in 2019, Pataigin is positioned in the high-growth rapid diagnostics market, with BACLIB targeting a clear unmet need in sepsis and other acute infections. The company has no disclosed funding or revenue, but its technology has the potential to disrupt standard-of-care microbiology if successfully commercialized. Pataigin's trajectory hinges on clinical validation and regulatory clearance. The company likely plans to pursue FDA 510(k) clearance or CLIA waiver for BACLIB, supported by clinical studies demonstrating accuracy versus conventional methods. Establishing a commercial partnership with a hospital system or diagnostics distributor would also be key to market entry. While the diagnostics space is competitive (e.g., BioFire FilmArray, T2 Biosystems), Pataigin's unique speed and direct-from-specimen approach offer differentiation. The company's near-term success depends on execution of these milestones.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or CLIA waiver for BACLIB60% success
• Q2 2026Publication of clinical validation study results80% success
• Q3 2026Commercial partnership with hospital system or diagnostics distributor50% success